AVDL News and Press, Avadel Pharmaceuticals plc From 02/17/21

Avadel Pharmaceuticals (AVDL) appointed 25-years industry veteran Richard Kim to the newly formed role of Chief Commercial Officer for leading all aspects of the U.S. commercial launch of the company’s lead program, once-nightly FT218, pending regulatory approv...

DUBLIN, Ireland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy, to...

Avadel's flagship compound, FT218, is on its way towards approval with the FDA. FT218 once nightly dose has been proven more efficient and better accepted by patients than competing products. Potential obstacle towards approval seen as minimal risk. Narcolepsy is an over-$1 bi...

DUBLIN, Ireland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced to...

Jazz Pharmaceuticals (JAZZ) appears to be starting to clear away a legal overhang with Xyrem lawsuits, according to Evercore ISI.There are a number of class action lawsuits on Xyrem that could fasten the generic entry to as early as 2023 from 2026, according to Evercore analyst Umer Raffat.Ev...

Avadel Pharmaceuticals (AVDL) rises 6% in premarket after submitting its marketing application to the FDA seeking approval for its lead candidate FT218, once-nightly formulation of sodium oxybate using Micropump technology for extended-release oral suspension, for the treatment of e...

DUBLIN, Ireland, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for FT218, an investigational, once-nightly formulation of sodium oxybate designe...

Larimar Therapeutics ([[LRMR]] -3.4%), Avadel Pharmaceuticals ([[AVDL]] +1.7%) and Applied Therapeutics ([[APLT]] +2.5%) have been selected to be included in the NASDAQ Biotechnology Index.The addition to the index will become effective prior to market open on Monday, December 21.In compariso...

DUBLIN, Ireland, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, ...

Avadel's FT218 is claimed to be a better version of Xyrem. Xyrem, or rather sodium oxybate, is a multibillion-dollar market. Key competition now is, however, Xywav. For further details see: Avadel's Xyrem Competitor: A Quick Overview